Imatinib Mesylate Related Immunolological Changes in Chronic Myeloid Leukemia
Abstract
ABSTRACT
Background: Chronic myelogenous leukemia (CML) is a pluripotential stem cell with
specific haematological features and characteristic cytogenetic and molecular changes
which are Philadelphia (Ph) chromosome and the resulting chimeric BCR-ABL gene that
present in more than 95 percent of patients. Different types of treatment are available for
CML patients one of them is Imatinib Mesylate (Gleevec, Glivec) that has become
standard therapy for CML works by binding to the adenosine triphosphate (ATP) binding
site of BCR-ABL, resulting in competitive inhibition of its enzymatic activity which plays the
key role in the pathogenesis of CML. Imatinib mesylate effect on tyrosine kinases which
are involved in various intracellular signaling pathways and affects immune response.
Objectives: To evaluate the levels of IgG, IgM and IgA in addition to C3 and C4 in CML
patients treated with imatinib mesylate and correlate them with different haematological
parameters.
Methods: Thirty CML patients on imatinib mesylate therapy treated in the National Center
of Haematology (Baghdad) during the year 2013, hematological parameters (including
complete blood count and blood film) and immunological parameters (including IgG, IgM,
IgA, C3 and C4) serum levels were studied and compared to 30 normal controls.
Results: There were no significant difference between patients and control regarding all
the studied immunological parameters, and there were no correlations between these
parameters and hematological parameters.
Conclusion: The present results indicate that the immunological changes related to
imatinib mesylate therapy are not significant. Further studies are still recommended.
Copyright (c) 2014 Iraqi Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Share — copy and redistribute the material in any medium or format
Under the following terms:
-
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
-
NonCommercial — You may not use the material for commercial purposes.
-
NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
